← Human Trials & Peer-Reviewed Studies
A phase II dose evaluation pilot feasibility randomized controlled trial of cholecalciferol in critically ill children with vitamin D deficiency (VITdAL-PICU study).
Plain-language guide to PMID 37580663 (2023): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 67 children.
Key Facts
- PMID
- 37580663
- Journal
- BMC pediatrics
- Year
- 2023
- Study type
- Randomized Controlled Trial
- Authors
- O'Hearn K et al. (21 authors)
- DOI
- 10.1186/s12887-023-04205-9
- Registered trial
- NCT02452762
What This Study Did, in Plain Language
What Was Tested
Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.
Secondary objectives were to evaluate for adverse events and assess the feasibility of a phase III trial.
Why It Was Studied
There have been no published trials of rapid normalization of VDD in the pediatric ICU.
Who Took Part
The abstract describes 67 children taking part.
By PubMed's age tags, the people studied were children and adults.
Participants, care givers, and outcomes assessors were blinded.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled, multicenter and pilot.
The children were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.
As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.
A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.
More than one site took part, so the children came from several places.
The researchers conducted a multicenter placebo-controlled phase II pilot feasibility randomized clinical trial from 2016 to 2017.
What Was Measured
Topics PubMed links to this paper include Cholecalciferol, Critical Illness, Quality of Life, Feasibility Studies, Vitamin D, Vitamins and Vitamin D Deficiency.
Author keywords: Critical care, Pediatrics and Randomized controlled trial.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 67 children.
Results are reported in around 10 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2023 (BMC pediatrics), a journal based in England.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.